Navigation Links
Endocare Reports 2007 Annual and Fourth Quarter Financial Results
Date:3/4/2008

Achieves 20 Percent Year-Over-Year Growth in Cryoablation Procedures, 18

Percent Year-Over-Year Growth in Probe Sales, 11 Percentage Point

Improvement in Gross Margin for Year

IRVINE, Calif., March 4 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, today reported that the estimated number of domestic cryoablation procedures grew by more than 20 percent, total revenues grew by 6 percent and gross margin (gross profit as a percent of total revenues) improved by 11 percentage points in the year ended December 31, 2007 compared to the 2006 totals.

Year-End Results

Total revenues from continuing operations for the 2007 year were $29.7 million, compared to $28.0 million for 2006. From continuing operations, gross margin for the year was 67.1 percent, an 11 percentage point improvement compared to full year 2006 gross margin of 55.9 percent.

For 2007, operating expenses from continuing operations (which exclude the effects in 2007 of a litigation settlement) were $29.9 million, compared to $31.1 million in 2006. Net loss for the year was $8.9 million, or $0.80 loss per share, compared to a net loss of $10.8 million, or $1.07 loss per share in 2006, which included income from discontinued operations of $311,000 or $0.03 earnings per share.

Endocare Chairman, CEO and President Craig T. Davenport said, "We are pleased to close a strong year of performance for Endocare demonstrated by double-digit growth in procedures year-over-year, solid improvement in gross margin and progress in reducing operating expenses."

The balance sheet as of December 3 common stock warrants - (775) - (3,716)

Subtotal (2,144) (3,470) (7,642) (13,256)

Add: Stock compensation expense 952 821 3,880 2,797

Adjusted EBITDA $(1,192) $(2,649) $(3,762) $(10,459)

ENDOCARE, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands)

December 31,

2007 2006

ASSETS

Current assets:

Cash and cash equivalents $7,712 $1,811

Accounts receivable, net 3,530 4,161

Inventories, net 3,022 2,260

Prepaid expenses and other current assets 2,081 1,284

Total current assets 16,345 9,516

Property and equipment, net 850 1,040

Intangibles, net 3,077 3,613

Investments and other assets 989 2,077

Total assets $21,261 $16,246

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable $2,194 $3,393

Accrued compensation 3,895 3,000

Other accrued liabilities 3,034 3,594

Line of credit 880 -

Capital lease obligation, current portion 28 -

Total current liabilities 10,031 9,987

Capital lease obligation 84 -

Deferred compensation 227 74

Common stock warrants - 1,307

Stockholders' equity:

Preferred stock, $0.001 par value; 1,000 shares

authorized; none issued and outstanding - -

Common stock, $0.001 par value; 50,000 shares

authorized; 11,762 and 10,226 issued and

outstanding as of December 31, 2007 and

December 31, 2006, respectively 12 10

Additional paid-in capital 200,663 181,310

Accumulated deficit (189,756) (176,442)

Total stockholders' equity 10,919 4,878

Total liabilities and stockholders' equity $21,261 $16,246

1, 2007 showed cash and cash equivalents of $7.7 million, total assets of $21.3 million and total stockholders' equity of $10.9 million. The Company had access to an additional $2.3 million under its line of credit with Silicon Valley Bank as of December 31, 2007 and also has continuing access to funds under its stock purchase agreement announced in October 2006.

Fourth Quarter Results

For the fourth quarter of 2007, the estimated number of domestic cryoablation procedures performed was up slightly, to 2,269, from 2,220 in the prior-year period. Total revenues from continuing operations for the fourth quarter of 2007 were $6.9 million, down from $7.1 million for the prior-year period. Cryoablation procedures with no service component, consisting of only disposable product sales, accounted for 87 percent of total procedures in the fourth quarter of 2007 and 80 percent in the prior-year period resulting in slightly lower average revenues per procedure in the fourth quarter of 2007. From continuing operations, gross margin for the fourth quarter of 2007 increased to 67.1 percent, compared to 62.9 percent in the fourth quarter of 2006.

Operating expenses from continuing operations for the fourth quarter of 2007 were $7.1 million compared to $8.4 million in the fourth quarter of 2006 and $7.1 million in the third quarter of 2007 (which exclude the effects of a litigation settlement in the third quarter of 2007). Loss from continuing operations for the fourth quarter of 2007 was $2.4 million, or $0.21 loss per share. For the fourth quarter of 2006, loss from continuing operations was $3.0 million, or $0.30 loss per share.

Adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA), which excludes non-cash stock compensation expense, was a loss of $1.2 million for the fourth quarter of 2007, compared to an adjusted EBITDA loss of $2.6 million for the fourth quarter of 2006. A reconciliation of the differences between the GAAP net losses and the adjusted EBITDA losses is included in an accompanying table.

Davenport said, "Following strong growth in procedures in the first three quarters, our fourth quarter, in terms of procedure and revenue growth, was somewhat lighter than we expected. Nevertheless, we remain confident in our overall progress and the outlook for our business. For instance, we are very encouraged by the recent surge in interest among physicians and leading cancer centers in focal cryoablation (or the 'male lumpectomy') and in salvage cryoablation, for the significant number of men whose prostate cancer has recurred following radiation therapy. This growing interest is evidenced by third-party sponsorship of educational seminars and new studies in the first half of 2008 at leading institutions throughout the United States on these key clinical segments of our market."

Chief Financial Officer Michael R. Rodriguez said, "As we indicated previously, our internal goal was to reach positive adjusted EBITDA territory as we exited 2007 and on a sustained quarterly basis beginning at some point in the first half of 2008. We believe that our achievement of this goal may be delayed, primarily as a result of our ongoing obligation to advance the legal fees of our former officers. However, we remain committed to achieving positive adjusted EBITDA operations on a sustained basis, while also continuing to make the investments we believe are appropriate to grow our business."

New Business Metrics

As announced on the 2007 third quarter conference call, the Company will be augmenting and soon replacing procedure estimates as a business metric with probe sales data. Probe sales will be reported in two categories: straight probes, which are typically, although not always, used in prostate procedures and right-angle probes, which are typically used in procedures other than prostate procedures. Given the Company's migration to a disposable sales model, the increased variability in the way physicians use the Company's probes and the fact that customers are more often maintaining inventories of the Company's products, it has become more difficult to estimate precisely the number of procedures performed using the Company's products. In the interest of better visibility and more straightforward measures of progress, management has elected to provide these new metrics.

Year ended Three months ended

December 31, December 31,

2005 2006 2007 2006 2007

Estimated domestic cryoablation

procedures 6,407 7,802 9,373 2,220 2,269

Number of cryoprobes sold

Straight probes 29,943 33,598 38,909 9,180 9,057

Right-angle probes 2,803 4,590 6,308 1,391 1,671

Total 32,746 38,188 45,217 10,571 10,728

Conference Call

As previously announced, Endocare will host a conference call today, March 4, 2008, to discuss the Company's results for its year and fourth quarter ended December 31, 2007. The call will take place at 11:00 a.m. (Eastern) and will be broadcast live over the Internet. Web participants are encouraged to go to the Company's website (http://www.endocare.com/investors/webcasts.php) at least 15 minutes prior to the start of the call to register, download and install any necessary audio software. The online archived replay will be available immediately following the conference call at http://www.endocare.com/investors/webcasts.php.

Use of Non-GAAP Financial Measures

The Company uses, and this press release contains and the related conference call will include, the non-GAAP metric of adjusted EBITDA. The calculation of adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, and also excluding non-cash stock compensation expense, collectively "adjusted EBITDA") has no basis in GAAP. The Company's management believes that this non-GAAP financial measure provides useful information to investors, permitting a better evaluation of the Company's ongoing and underlying business performance, including the evaluation of its performance against its competitors in the healthcare industry. Management uses this non-GAAP financial measure for purposes of its internal projections and to evaluate the Company's financial performance.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in conformity with GAAP, and non-GAAP financial measures as reported by the Company may not be comparable to similarly titled amounts reported by other companies. A complete reconciliation of this non-GAAP financial measure for the applicable periods to the most directly comparable GAAP measures is presented in an accompanying table.

About Endocare

Endocare, Inc. -- http://www.endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

Statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties, including, without limitation, our internal goal of achieving positive adjusted EBITDA operations as described above. Among the important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in "Risk Factors" in the Company's Forms 10-K, Forms 10-Q and other filings with the Securities and Exchange Commission. Such risk factors include, but are not limited to, the following items: the Company may incur significant expenses in the future as a result of the Company's obligation to pay legal fees for and otherwise indemnify former officers and former directors in connection with the ongoing investigations and legal proceedings involving them; uncertainty relating to third party reimbursement; the Company has a limited operating history with significant losses and losses may continue in the future; the Company may require additional financing to sustain its operations and without it the Company may not be able to continue operations; the sale of the Company's common stock to Fusion Capital may cause dilution, and the sale of the shares of common stock acquired by Fusion Capital or Frazier Healthcare Ventures could cause the price of the Company's common stock to decline; the Company's business may be materially and adversely impacted by the loss of the Company's largest customer or the reduction, delay or cancellation of orders from this customer or if this customer delays payment or fails to make payment; the Company may be required to make state and local tax payments that exceed the Company's settlement estimates; uncertainty regarding the ability to convince health care professionals and third party payers of the medical and economic benefits of the Company's products; the risk that intense competition and rapid technological and industry change may make it more difficult for the Company to achieve significant market penetration; and uncertainty regarding the ability to secure and protect intellectual property rights relating to the Company's technology. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. The Company undertakes no obligation to revise, or update publicly, any forward-looking statements for any reason.

Investor Contact: Media Contact:

Matt Clawson Len Hall

Allen & Caron, Inc. Allen & Caron, Inc.

(949) 474-4300 (949) 474-4300

matt@allencaron.com len@allencaron.com

http://www.allencaron.com http://www.allencaron.com

For Additional Information:

Craig T. Davenport, CEO

Michael R. Rodriguez, CFO

Endocare, Inc.

(949) 450-5400

http://www.endocare.com

TABLES FOLLOW

ENDOCARE, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except for per share data)

Three Months Ended Dec. 31,

2007 2006

Total revenues $6,914 $7,120

Costs and expenses:

Cost of revenues 2,274 2,644

Research and development 620 714

Selling and marketing 3,493 3,797

General and administrative 2,950 3,844

Total costs and expenses 9,337 10,999

Loss from operations (2,423) (3,879)

Interest expense related to common stock

warrants - (775)

Interest (income) expense, net 12 (19)

Loss from continuing operations before taxes (2,435) (3,085)

Tax benefit on continuing operations - 41

Loss from continuing operations (2,435) (3,044)

Income from discontinued operations - 65

Net loss $(2,435) $(2,979)

Net income (loss) per share -- basic and

diluted:

Continuing operations $(0.21) $(0.30)

Discontinued operations - 0.01

Weighted average shares of common stock

outstanding: 11,640 10,177

ENDOCARE, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except for per share data)

Year Ended Dec. 31,

2007 2006

Total revenues $29,687 $27,990

Costs and expenses:

Cost of revenues 9,780 12,343

Research and development 2,555 2,781

Selling and marketing 14,855 15,195

General and administrative 12,506 13,107

Gain on legal settlement (677) -

Total costs and expenses 39,019 43,426

Loss from operations (9,332) (15,436)

Interest expense related to common stock

warrants - (3,716)

Interest (income) expense, net (391) (452)

Loss from continuing operations before taxes (8,941) (11,268)

Tax benefit on continuing operations - 192

Loss from continuing operations (8,941) (11,076)

Income from discontinued operations - 311

Net loss $(8,941) $(10,765)

Net income (loss) per share -- basic and

diluted:

Continuing operations $(0.80) $(1.10)

Discontinued operations - 0.03

Weighted average shares of common stock

outstanding: 11,122 10,084

ENDOCARE, INC. AND SUBSIDIARY

RECONCILIATION OF GAAP NET LOSS TO EARNINGS BEFORE INTEREST, TAXES,

DEPRECIATION, AMORTIZATION AND STOCK COMPENSATION EXPENSE

("ADJUSTED EBITDA")

(Unaudited)

(In thousands)

Three Months Ended Year Ended

December 31, December 31,

2007 2006 2007 2006

GAAP loss from continuing

operations $(2,435) $(3,044) $(8,941) $(11,076)

Add:

Depreciation 127 211 590 981

Amortization of intangibles 125 138 536 555

Interest expense 39 - 173 -

Less:

Interest expense related to


'/>"/>

SOURCE Endocare, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Endocare Announces That National Cancer Institute to Sponsor Study Comparing Cryoablation to Radiation Therapy for Pain Relief in Bone Cancer Patients
2. Endocare Reports 2007 Third Quarter and Nine-Month Results
3. Endocare Stock to Commence Trading on NASDAQ
4. Folic Acid in the Food Supply Reduces Birth Defects, but May Cause Extra Cancers, Reports the Harvard Womens Health Watch
5. CardiacQA Surpasses 20,000 Client Generated Nuclear Cardiology Reports
6. Sunrise Reports Preliminary Selected Financial and Operating Data for Fourth-Quarter 2007
7. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
8. Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium
9. Par Pharmaceutical Reports Fourth Quarter and Full Year 2007 Results
10. Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call
11. AMICAS Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
(Date:6/23/2016)... Research and Markets has announced ... Analysis (United States, China, Japan, Brazil, United Kingdom, Germany, ... offering. Surgical Procedure ... planners, provides surgical procedure volume data in a geographic ... in-depth analysis of growth drivers and inhibitors, including world ...
(Date:6/23/2016)... 23, 2016 The Biotechnology industry ... to present great opportunities to investors. Stock-Callers.com assesses the ... Corp. (NYSE: XON ), Vertex Pharmaceuticals Inc. ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... and receive your complimentary trade alerts at: ...
Breaking Medicine Technology: